Speranza Therapeutics and CoAssist Pharmacy Combat Opioid Crisis with Non-Invasive Therapy Access

Speranza Therapeutics, a prominent neuromodulation and pharmaceutical company based in Boca Raton, Florida, has announced a significant partnership with CoAssist Pharmacy, one of the nation's leading consignment pharmacies. This collaboration aims to enhance patient access to S.T. Genesis, an FDA-cleared medical device designed to manage opioid withdrawal symptoms.

The S.T. Genesis device, which can now be obtained via prescription through CoAssist Pharmacy, represents a significant step forward in the field of addiction treatment. Patients can have their physicians order the device through e-prescribing directly within their EHR/EMR systems, fax, or by calling CoAssist Pharmacy directly. The device is then delivered to the physician's office within 24 hours for patient use.

S.T. Genesis is revolutionary in the management of opioid withdrawal symptoms. It is placed externally in the left ear by a trained medical professional and begins to alleviate withdrawal symptoms within 30 minutes. Clinical results have shown that patients' Clinical Opioid Withdrawal Scores (COWS) decrease by 94% within an hour. The device remains in place for five days, completing the initial detoxification phase of recovery, after which patients can proceed to medication-assisted treatment (MAT).

Speranza Therapeutics stands out in the addiction treatment space by offering more reimbursement options for patients than any other company in the sector. This commitment is underscored by their partnership with CoAssist Pharmacy, which enables the efficient and timely delivery of the S.T. Genesis device to medical professionals and their patients. Sal Rafanelli, President and CEO of Speranza Therapeutics, emphasized the critical need to support the 47 million individuals in the United States who are misusing and abusing substances, including the deadly opioid Fentanyl. This partnership is a testament to Speranza’s dedication to making a significant impact on this patient population.

Michael Carr, Group Vice President of CoAssist Pharmacy, which operates under AssistRx, highlighted the importance of this partnership in streamlining the prescription process for physicians and enhancing patient care through advanced, automated technology. AssistRx is committed to transforming lives by simplifying access to therapy and ensuring that patients receive the necessary treatments more efficiently and effectively.

Speranza Therapeutics continues to innovate and disrupt the norms in medical device and pharmaceutical delivery. Their mission is to overcome the inherent challenges in providing effective treatment to patients with complex medical conditions through clinically proven therapeutics and technology.

AssistRx, the parent company of CoAssist Pharmacy, has developed a sophisticated blend of technology and expertise to support advanced therapy initiation and improve patient outcomes. Their solutions are designed to simplify the complex healthcare system, making it easier for patients to access and benefit from necessary treatments.

In conclusion, the partnership between Speranza Therapeutics and CoAssist Pharmacy marks a significant advancement in the field of opioid addiction treatment. By making the S.T. Genesis device more accessible and streamlining the prescription process, this collaboration aims to improve patient outcomes and offer a new level of care for those battling opioid addiction. Through innovative solutions and dedicated efforts, Speranza Therapeutics and AssistRx are working to transform the landscape of addiction treatment and patient care.